FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890168377> ?p ?o ?g. }

• W2890168377 endingPage "11006" @default.
• W2890168377 startingPage "11006" @default.
• W2890168377 abstract "11006 Background: CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T cells. It consists of LV305, a dendritic cell targeting lentiviral vector encoding NY-ESO-1, and a boost with G305, an NY-ESO-1 recombinant protein plus GLA-SE, a TLR-4 agonist. An LV305 phase 1 study demonstrated a 1-yr survival of 81% and induction of anti-NY-ESO-1 T cells in sarcoma patients (pts). This first-in-human study of CMB305 examined safety, immunogenicity, and efficacy in pts with NY-ESO-1 positive (+) solid tumors. Methods: Adults with previously treated NY-ESO-1 + sarcomas, NSCLC, ovarian cancer were enrolled in a 3+3 dose-escalation with an expansion phase 1 study. The CMB305 regimen included 4 intradermal injections of LV305 at 10 9 or 10 10 vector genomes, alternating with 3 intramuscular G305 injections at 250 µg for 3 months, then bimonthly G305 injections up to 1 yr. Results: As of 31Dec2016, 25 pts with STS (15 synovial (SS), 8 myxoid/round cell liposarcoma (MRCL), 2 other) were evaluable for safety; 23 SS/MRCL pts were evaluable for immune response (IR) and efficacy. All SS and MRCL pts received prior therapy for locally advanced/metastatic disease, 67% > = 2 prior chemo regimens. No DLTs were observed; treatment related AEs were grade 1 and 2, except 1 pt with grade 3 SAE (prostatic pain). Of 11 SS/MRCL pts tested, 64% pts developed NY-ESO-1 specific T cells and 72% pts anti-NY-ESO-1 antibodies. T cell receptor sequencing indicated increased clonality, and antigen spreading after CMB305. Best response by immune related response criteria was stable disease in 8/15 (53%) SS pts and 6/8 (75%) MRCL pts. The 3 month PFS rate was 74% and 75% for SS and MRCL pts. Median survival has not been reached with 1-yr survival rate of 86% and 100% for SS and MRCL pts. Conclusions: CMB305 is safe, well tolerated, and demonstrates a survival rate that is favorable when compared with approved agents for recurrent STS. CMB305 resulted in a stronger and broader integrated IR than LV305, including antigen spreading. These data warrant further investigation of CMB305 as a monotherapy in a randomized clinical study in STS. A randomized study of CMB305 in combination with atezolizumab in SS/MRCL pts is ongoing. Clinical trial information: NCT02387125." @default.
• W2890168377 created "2018-09-27" @default.
• W2890168377 creator A5000164383 @default.
• W2890168377 creator A5000193426 @default.
• W2890168377 creator A5008969784 @default.
• W2890168377 creator A5025625281 @default.
• W2890168377 creator A5026451121 @default.
• W2890168377 creator A5033798832 @default.
• W2890168377 creator A5037223246 @default.
• W2890168377 creator A5043801603 @default.
• W2890168377 creator A5068433389 @default.
• W2890168377 creator A5072672228 @default.
• W2890168377 creator A5073906112 @default.
• W2890168377 creator A5078046623 @default.
• W2890168377 creator A5084180707 @default.
• W2890168377 creator A5087234749 @default.
• W2890168377 date "2017-05-20" @default.
• W2890168377 modified "2023-10-18" @default.
• W2890168377 title "Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)." @default.
• W2890168377 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11006" @default.
• W2890168377 hasPublicationYear "2017" @default.
• W2890168377 type Work @default.
• W2890168377 sameAs 2890168377 @default.
• W2890168377 citedByCount "14" @default.
• W2890168377 countsByYear W28901683772017 @default.
• W2890168377 countsByYear W28901683772018 @default.
• W2890168377 countsByYear W28901683772019 @default.
• W2890168377 countsByYear W28901683772020 @default.
• W2890168377 countsByYear W28901683772021 @default.
• W2890168377 countsByYear W28901683772022 @default.
• W2890168377 crossrefType "journal-article" @default.
• W2890168377 hasAuthorship W2890168377A5000164383 @default.
• W2890168377 hasAuthorship W2890168377A5000193426 @default.
• W2890168377 hasAuthorship W2890168377A5008969784 @default.
• W2890168377 hasAuthorship W2890168377A5025625281 @default.
• W2890168377 hasAuthorship W2890168377A5026451121 @default.
• W2890168377 hasAuthorship W2890168377A5033798832 @default.
• W2890168377 hasAuthorship W2890168377A5037223246 @default.
• W2890168377 hasAuthorship W2890168377A5043801603 @default.
• W2890168377 hasAuthorship W2890168377A5068433389 @default.
• W2890168377 hasAuthorship W2890168377A5072672228 @default.
• W2890168377 hasAuthorship W2890168377A5073906112 @default.
• W2890168377 hasAuthorship W2890168377A5078046623 @default.
• W2890168377 hasAuthorship W2890168377A5084180707 @default.
• W2890168377 hasAuthorship W2890168377A5087234749 @default.
• W2890168377 hasConcept C126322002 @default.
• W2890168377 hasConcept C136948725 @default.
• W2890168377 hasConcept C141071460 @default.
• W2890168377 hasConcept C143998085 @default.
• W2890168377 hasConcept C203014093 @default.
• W2890168377 hasConcept C2776910622 @default.
• W2890168377 hasConcept C2780868878 @default.
• W2890168377 hasConcept C2781413609 @default.
• W2890168377 hasConcept C71924100 @default.
• W2890168377 hasConcept C8891405 @default.
• W2890168377 hasConcept C90924648 @default.
• W2890168377 hasConceptScore W2890168377C126322002 @default.
• W2890168377 hasConceptScore W2890168377C136948725 @default.
• W2890168377 hasConceptScore W2890168377C141071460 @default.
• W2890168377 hasConceptScore W2890168377C143998085 @default.
• W2890168377 hasConceptScore W2890168377C203014093 @default.
• W2890168377 hasConceptScore W2890168377C2776910622 @default.
• W2890168377 hasConceptScore W2890168377C2780868878 @default.
• W2890168377 hasConceptScore W2890168377C2781413609 @default.
• W2890168377 hasConceptScore W2890168377C71924100 @default.
• W2890168377 hasConceptScore W2890168377C8891405 @default.
• W2890168377 hasConceptScore W2890168377C90924648 @default.
• W2890168377 hasIssue "15_suppl" @default.
• W2890168377 hasLocation W28901683771 @default.
• W2890168377 hasOpenAccess W2890168377 @default.
• W2890168377 hasPrimaryLocation W28901683771 @default.
• W2890168377 hasRelatedWork W1519040467 @default.
• W2890168377 hasRelatedWork W1572342804 @default.
• W2890168377 hasRelatedWork W1992939082 @default.
• W2890168377 hasRelatedWork W2000744151 @default.
• W2890168377 hasRelatedWork W2030908446 @default.
• W2890168377 hasRelatedWork W2084789735 @default.
• W2890168377 hasRelatedWork W2134492004 @default.
• W2890168377 hasRelatedWork W2397255149 @default.
• W2890168377 hasRelatedWork W2469610592 @default.
• W2890168377 hasRelatedWork W2888060141 @default.
• W2890168377 hasVolume "35" @default.
• W2890168377 isParatext "false" @default.
• W2890168377 isRetracted "false" @default.
• W2890168377 magId "2890168377" @default.
• W2890168377 workType "article" @default.